SCHEMBL620594

SCHEMBL620594

NCc1cc(F)c(F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 7/20 0.46
LOXL2 Q9Y4K0 2/20 0.39
IDO1 P14902 2/20 0.33
AGXT P21549 2/20 0.33
TAAR1 Q96RJ0 2/20 0.33
MEN1 O00255 2/20 0.33
RAD52 P43351 2/20 0.33
RECQL P46063 2/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
MPO P05164 1/20 0.33
GAPDH P04406 1/20 0.33
THRB P10828 1/20 0.33
APEX1 P27695 1/20 0.33
BLM P54132 1/20 0.33
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13527770 0.94 LOXL2 (0.42) DPP4LOXL2IDO1AGXTTAAR1
SCHEMBL31346729 0.88 LOXL2 (0.42) DPP4LOXL2TAAR1MEN1RAD52
SCHEMBL29467943 0.81 ALDH1A1 (0.37) DPP4LOXL2IDO1AGXTTAAR1
SCHEMBL4889962 0.81 ALDH1A1 (0.37) DPP4LOXL2IDO1AGXTTAAR1
SCHEMBL29467970 0.81 ALDH1A1 (0.37) DPP4LOXL2IDO1AGXTTAAR1
SCHEMBL1765257 0.79 PNMT (0.39) DPP4LOXL2TAAR1TDP1HTR2A
SCHEMBL2039343 0.79 KDM1A (0.35) DPP4LOXL2IDO1AGXTTAAR1
SCHEMBL30350517 0.79 PNMT (0.39) DPP4LOXL2TAAR1TDP1HTR2A
SCHEMBL856202 0.79 KDM1A (0.44) DPP4LOXL2IDO1AGXTTAAR1
SCHEMBL28147905 0.78 LOXL2 (0.37) DPP4LOXL2TAAR1MEN1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271292-A Synthesis method of drug for treating new crown drug Enxi Qu Wei raw material drug 北京康立生医药技术开发有限公司 2024-07-02 CN claimed
CN-117466729-A Synthesis method of 2,4, 5-trifluoro phenylacetic acid 山东国邦药业有限公司 2024-01-30 CN claimed
CN-114853741-B Preparation method of novel coronavirus main protease inhibitor 苏州立新制药有限公司 2023-08-04 CN claimed
CN-116082257-A Synthesis method of entecavir intermediate 浙江大学杭州国际科创中心 2023-05-09 CN claimed
CN-114853741-A Preparation method of novel coronavirus main protease inhibitor 苏州立新制药有限公司 2022-08-05 CN claimed
EP-4683919-A1 VANIN-1 INHIBITORS Athos Therapeutics, Inc. (US) 2026-01-28 EP disclosed
EP-4635568-A2 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA Pharmaceuticals Inc. (US) 2025-10-22 EP disclosed
EP-3672954-B1 COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-08-13 EP disclosed
US-20250197385-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-06-19 US disclosed
US-20250163029-A1 PYRIDONE OR PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2025-05-22 US disclosed
US-20250115620-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-10 US disclosed
WO-2025058977-A1 MODULATORS OF CORONAVIRUS 3C-LIKE PROTEASE AND USES THEREOF Vir Biotechnology, Inc. (US) 2025-03-20 WO disclosed
CN-1620433-A pyrrolidine derivatives as endothelin converting enzyme inhibitors HOFFMANN LA ROCHE (CH) 2005-05-25 CN disclosed
US-6858651-B2 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-02-22 US disclosed
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-6452056-B1 REDUCING FLUORINATED BENZONITRILE TO A BENZYLAMINE WHICH IS REPLACED WITH A HYDROXYL GROUP ASAHI GLASS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed
EP-1114809-A1 PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES Asahi Glass Co., Ltd. (JP) 2001-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197385-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, CYP27A1, CYP11B2 DPP4 566/4885LOXL2 1837/4885IDO1 3517/4885
US-20250115620-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF SDHA, SDHB, DHFR DPP4 583/4885LOXL2 4558/4885IDO1 1733/4885
US-20250163029-A1 PYRIDONE OR PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF DPYD, PNPO, TYMP DPP4 439/4885LOXL2 3084/4885IDO1 417/4885
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP DPP4 42/4885LOXL2 2521/4885IDO1 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.